Piper Sandler Upgrades Teva Pharma (TEVA) to Overweight, 'The Times They Are A-Changin’'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/4/2026
- Wall Street ends lower as Middle East tensions escalate
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Broadcom's sales and AI chip forecast comes in below expectations, shares tumble
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Oil gains as Middle East hostilities flare
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Wall Street ends lower as Middle East tensions escalate
- After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
- After-Hours Stock Movers: PANW, CRWD, ZS, GTLB, ULTA
- After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
- After-Hours Stock Movers: DELL, MDB, AEO, NTAP, GAP, S, ADSK
- After-Hours Stock Movers: CRM, MRVL, SNOW, HPQ, DDOG, MDB, P, SNPS, BRZE, NCNO
4 small and mid-cap biopharma stocks to own according to BofA
February 9, 2024 8:00 PM ESTBofA Global Research has published a new analysis of the US biopharmaceutical sector, highlighting their preferred small- and mid-cap (SMID) stock selections in this field.
From a broader perspective, BofA believes the fundamentals of the biopharma sector remain solid, evidenced by the productivity of research and development (R&D) and external validation through mergers and acquisitions (M&A) activity.
Thanks to favorable conditions within the industry, the outlook on the broader group has become more positive compared to previous years, analysts led by Jason M. Gerberry said.
Heading into 2024, we are... More
